Match!
Niels Vande Casteele
University of California, San Diego
132Publications
22H-index
1,964Citations
Publications 132
Newest
#1Rish K. Pai (Mayo Clinic)H-Index: 21
#2Reena Khanna (UWO: University of Western Ontario)H-Index: 21
Last.Vipul JairathH-Index: 17
view all 8 authors...
The Robarts Histopathology Index (RHI) is a recently validated instrument that measures histological disease activity in ulcerative colitis.1 Given the increasing importance and use of histology in UC as a treatment outcome, additional evaluation and clarification of the definitions for histological remission and response using the RHI is needed. During the development of the RHI, we demonstrated that most patients in clinical or endoscopic remission had an RHI≤6. However, an RHI≤6 should not be...
#1Robert Battat (UCSD: University of California, San Diego)H-Index: 10
#2Parambir S. Dulai (UCSD: University of California, San Diego)H-Index: 19
Last.Niels Vande Casteele (UCSD: University of California, San Diego)H-Index: 22
view all 4 authors...
#2Lisa M. ShackeltonH-Index: 10
Last.Niels Vande Casteele (UCSD: University of California, San Diego)H-Index: 22
view all 3 authors...
Monoclonal antibody (mAb) therapies have revolutionized the treatment of several chronic inflammatory diseases, including the inflammatory bowel diseases (IBD), Crohn’s disease, and ulcerative colitis. While efficacious, responses to these therapies vary considerably from patient to patient, due in part to inter- and intra-individual variability in pharmacokinetics (PK) and drug exposure. The concept of personalized medicine to monitor drug exposure and to adjust dosing in individual patients is...
#1Siddharth Singh (UCSD: University of California, San Diego)H-Index: 36
#2Parambir S. Dulai (UCSD: University of California, San Diego)H-Index: 19
Last.WilliamJSandborn (UCSD: University of California, San Diego)H-Index: 134
view all 7 authors...
#1Christopher Ma (U of C: University of Calgary)H-Index: 11
#2Nicola R Panaccione (UWO: University of Western Ontario)
Last.Siddharth Singh (UCSD: University of California, San Diego)H-Index: 36
view all 12 authors...
#1Niels Vande Casteele (UCSD: University of California, San Diego)H-Index: 22
#2Jenny JeyarajahH-Index: 2
Last.WilliamJSandborn (UCSD: University of California, San Diego)H-Index: 134
view all 5 authors...
Background & Aims Therapeutic drug monitoring might be used to personalize infliximab treatment of patients with ulcerative colitis (UC), although exposure thresholds associated with endoscopic healing are uncertain. We aimed to determine infliximab concentration thresholds associated with endoscopic outcomes during induction and maintenance therapy for patients with UC. Methods We analyzed data from 484 patients with active UC included in 2 randomized controlled trials of infliximab vs placebo....
#1Konstantinos Papamichael (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 16
#2Adam S. Cheifetz (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 32
Last.Shane M. Devlin (U of C: University of Calgary)H-Index: 17
view all 16 authors...
Background & Aims Therapeutic drug monitoring (TDM) is widely available for biologic therapies in patients with inflammatory bowel disease (IBD). We reviewed current data and provided expert opinion regarding the clinical utility of TDM for biologic therapies in IBD. Methods We used a modified Delphi method to establish consensus. A comprehensive literature review was performed regarding the use of TDM of biologic therapy in IBD and presented to international IBD specialists. Subsequently, 28 st...
12345678910